Moreover, multiple studies have demonstrated that the degree of ERBB2 amplification as measured by quantitative copy number—a proxy for the degree of HER2 addiction in a tumor—is a predictor of response, with higher copy number associated with better outcomes (24–26). The gene discussed is ERBB2; the disease is neoplasm.